Amgen is going all in on a three-indication collaboration with an Ann Arbor, MI, biotech.
The California pharma has elected to move forward with all three autoimmune programs in its $240 million pact with EVOQ Therapeutics, the companies said Wednesday. EVOQ received an undisclosed milestone payment.
